

initial

reauthorization

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Somavert (pegvisomant) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE

ACTION/DESCRIPTION